Proposed amendments to NICE's HTA methods criticised

October 2014
PharmacoEconomics & Outcomes News;Oct2014, Vol. 713 Issue 1, p8
The article reports on commentaries published in the journal "PharmacoEconomics," which include one by Mike Paulden from University of Alberta, Edmonton, on NICE's previous amendments to its methods for health technology appraisal (HTA) and another by Suzanne R. Hill and Leslie G. Olson from University of Melbourne on Paulden and colleagues' criticism.


Related Articles

  • NICE result for Exogen and Watch BP Home A.  // PharmacoEconomics & Outcomes News;1/26/2013, Issue 670, p11 

    The article reports that a medical technology guidance supporting the Exogen ultrasound bone healing system and the WatchBP Home A device has been published by the National Institute for Health and Clinical Excellence (NICE) in Great Britain.

  • Health technology assessment under scrutiny. Jessop, Nathan // Pharmaceutical Technology Europe;Sep2011, Vol. 23 Issue 9, p22 

    The article discusses the management of expensive treatments by healthcare technology assessment (HTA), a multidisciplinary field of policy analysis. As stated, Great Britain's HTA the National Institute for Health and Clinical Excellence has caused frustration to the pharmaceutical industry in...

  • Subgroups and Heterogeneity in Cost-Effectiveness Analysis. Sculpher, Mark // PharmacoEconomics;2008, Vol. 26 Issue 9, p799 

    The National Institute for Health and Clinical Excellence (NICE) is required to consider cost effectiveness when issuing guidance about the use of health technologies within the UK NHS. Cost effectiveness is a means of supporting a system objective of maximizing population health gain from the...

  • Cautions Regarding the Fitting and Interpretation of Survival Curves: Examples from NICE Single Technology Appraisals of Drugs for Cancer. Connock, Martin; Hyde, Chris; Moore, David // PharmacoEconomics;2011, Vol. 29 Issue 10, p827 

    The UK National Institute for Health and Clinical Excellence (NICE) has used its Single Technology Appraisal (STA) programme to assess several drugs for cancer. Typically, the evidence submitted by the manufacturer comes from one short-term randomized controlled trial (RCT) demonstrating...

  • A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States. Mavranezouli, Ifigeneia // PharmacoEconomics;2010, Vol. 28 Issue 12, p1109 

    Economic evaluation of health technologies in the form of cost-utility analysis is increasingly advocated. The most common outcome measure in this type of analysis is the QALY. In order to estimate QALYs, appropriate utility values are required. The objective of this review was to identify and...

  • When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development? Longworth, Louise; Youn, JiHee; Bojke, Laura; Palmer, Stephen; Griffin, Susan; Spackman, Eldon; Claxton, Karl // PharmacoEconomics;2013, Vol. 31 Issue 2, p137 

    Background: There is growing interest internationally in linking reimbursement decisions with recommendations for further research. In the UK, the National Institute for Health and Clinical Excellence (NICE) can issue guidance to approve the routine use of a health intervention, reject routine...

  • Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization. Craig, Dawn; Rice, Stephen; Paton, Fiona; Fox, David; Woolacott, Nerys // PharmacoEconomics;2013, Vol. 31 Issue 2, p101 

    The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of retigabine (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adults with partial-onset seizures in epilepsy, with and without secondary...

  • Europe's Health Sector Pushes Review of New Therapies' Value. Moran, Nuala // BioWorld International;12/14/2011, Vol. 16 Issue 50, p1 

    The article reports on the collaboration of the healthcare sector in Europe to push for industry involvement in the health technology assessments (HTA) that are being performed to measure the added-value of therapies and used as the basis of deciding whether or not to pay for them. A joint...

  • NICE considers the patient.  // PharmacoEconomics & Outcomes News;2/21/2009, Issue 572, p3 

    The article reports on a study by the British National Institute for Health & Clinical Excellence (NICE), investigating how value, to patients, is explored when new health technologies are considered, and new guidance on engaging patients in decision surrounding prescribed medicines. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics